Hanmi wins Korean patent for antineoplastic composition

Published: 2013-01-02 06:56:00

Updated: 2013-01-02 06:56:00

Hanmi Pharm said Thursday that it acquired a Korean patent for a composition that may safely extend the expiration date of a target anticancer drug up to a couple of years.

The title of this invention is “Pharmaceutical composition containing amide derivative and its pharmaceutically acceptabl...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK